Talin functions both as a regulator of integrin affinity and as an important mechanical link between integrins and the cytoskeleton. Using genetic deletion of talin, we show for the first time that the capacity of talin to activate integrins is required for fibrin clot retraction by platelets. To further dissect which talin functions are required for this process, we tested clot retraction in platelets expressing a talin1(L325R) mutant that binds to integrins, but exhibits impaired integrin activation ascribable to disruption of the interaction between talin and the membrane-proximal region (MPR) in the β-integrin cytoplasmic domain. Talin-deficient and talin1(L325R) platelets were defective in retracting fibrin clots. However, the defect in clot retraction in talin1(L325R) platelets, but not talin-deficient platelets, was rescued by extrinsically activating integrins with manganese, thereby proving that integrin activation is required and showing that talin1(L325R) can form functional links to the actin cytoskeleton.
Introduction
Upon vascular injury, platelets encounter collagen and soluble factors that initiate intracellular signaling that upregulates integrin ligand-binding affinity (activation) required for platelet adhesion and aggregation, two key processes in thrombus initiation and growth 1 . Subsequently, α IIbβ3 integrin-dependent retraction of clots by platelets promotes thrombus stability and wound healing 2 . Thus, modulation of integrin activation and the mechanical linkage of integrins to the actin cytoskeleton are critical for primary hemostasis.
A necessary final step in activating integrins is the binding of talin to the β integrin cytoplasmic domain. Talin comprises an N-terminal FERM (four-pointone/ezrin/radixin/moesin) domain and a 200kDa flexible rod domain. The FERM domain binds to β integrin cytoplasmic domains (tails), phosphatidylinositol phosphate kinase type 1γ-90 (PIPKIγ-90), and layilin. The rod domain has multiple binding sites for vinculin and actin 3 . There are two talin isoforms, and global genetic deletion of talin1 in mice is early embryonic lethal necessitating tissue-specific knock-out approaches 4 . Previously, we have shown that platelet-specific deletion of talin1 using a conditional talin1 knock-out mouse (Tln1 (fl/fl) ) crossed with a mouse expressing a platelet-specific Cre under control of the platelet factor-4 promoter (PF4-Cre) 5 results in impaired agonist-induced integrin activation in platelets 6 . Furthermore, platelets from mice expressing a β 3(L746A) mutation that disrupts talin binding to β 3 integrin phenocopy the defects in α IIbβ3 activation observed in talin-deficient platelets [6] [7] [8] . Together, these studies strongly suggest that binding of talin to integrins is required for integrin activation in platelets. However, deletion of talin or a β 3(L746A) mutation ablate the talindependent link between integrins and the actin cytoskeleton 9, 10 .
Recent structural and biochemical studies by Wegener et al. suggest that talin interactions with a membrane-proximal region (MPR) of integrins is necessary for integrin activation 11 . These investigators identified a talin1(L325R) mutation predicted to inhibit integrin activation by disrupting the talin-β3 integrin MPR. Furthermore, the talin1(L325R) mutation only slightly reduced the affinity of the talin FERM domain for a chimeric peptide containing the MPR of integrin β 3 11 . Together, their findings suggest that talin1(L325R) would be defective in integrin activation, yet able to mediate other functions such as binding to PIPKIγ-90 and linking integrins to the actin cytoskeleton. To test the hypothesis that talin-integrin MPR interactions are required for integrin function in vivo, we generated mice expressing talin1(L325R) in platelets. Our results demonstrate that agonist-induced activation of platelet integrins is dependent on the talinintegrin MPR interaction and that this interaction is necessary for fibrin clot retraction by platelets.
Methods

Mice
Tln1
(fl/fl) ,PF4-Cre mice have been described in detail 8 . Conditional Tln1(L325R) mutant mice were generated by gene-targeting using a targeting vector illustrated in Supplemental Figure 2 and characterized as described in Supplemental Methods. Mice were housed in the University of California, San Diego, animal facility, and experiments were approved by the University's Institutional Animal Care and Use Committee.
Platelet function Soluble fibrinogen and 9EG7 binding assays were performed on washed platelets exactly as previously described 8 . Measurement of clot retraction was performed using plateletrich plasma obtained from blood drawn into 1/10 volume of 3.8% sodium citrate and 1 volume of modified Tyrode's buffer (140mM NaCl, 2.7mM KCl, 0.4m NaH 2 PO 4 .H 2 O, 10mM NaHCO 3 , 5mM Dextrose, 10mM Hepes). Platelets were diluted to 3X10 8 /ml with platelet-poor plasma obtained from wild type mice. After the addition of 2mM CaCl 2 , platelet-rich plasma (PRP) was added to siliconized glass cuvettes containing a paperclip and clot retraction was initiated with the addition of 1U/ml bovine thrombin (Sigma). In some samples 0.5mM MgCl2, 10µM cytochalasin D or 50µM eptifibatide was added to PRP 5 min prior to thrombin. Samples were incubated at 25°C for 2h and clot retraction analyzed by imaging the clot retraction and weighing the residual serum after removing the clot to calculate the percent of serum extruded from the clot.
Affinity chromatography Tln1
(L325R/fl) ,Cre+ and Tln1 (wt/fl) ,Cre+ platelets were solubilized as previously described 12 . Affinity chromatography was performed using recombinant integrin cytoplasmic tails bound to NeutrAvidin Resin (Thermo Scientific) as previously described 12, 13 . Bound proteins were fractionated by SDS-PAGE and analyzed by Western blotting with antitalin 8d4 (Sigma-Aldrich) antibody. Binding of recombinant integrin tails to the resin was verified by Coomassie Blue staining. Signal was detected and quantified using an Odyssey imaging system (LI-COR Biosciences).
Results and Discussion
Talin(L325R) impairs integrin activation by selectively disrupting membraneproximal interactions with integrins.
To test whether interaction of talin with the MPR of integrins is necessary for agonistinduced activation of integrins in platelets, we generated mice carrying a single amino acid substitution (L325R) in talin1 by gene-targeting. Considering global genetic deletion of talin1 is embryonic lethal, and that a talin1(L325R) mutation is predicted to impart a strong loss-of-function effect, Tln1
(L325R/wt) mice were crossed with Tln1 (flox/flox) ,PF4-Cre+ mice so that talin1(L325R) was selectively expressed in platelets. Affinity chromatography showed that talin1(L325R) bound β 1 and β 3 integrin tails similar to wild type talin1 ( Figure 1A) . In addition to integrins, talin also binds to PIPKIγ-90, a protein that contributes to anchoring the cytoskeleton to the plasma membrane 14 . Importantly, the talin1(L325R) mutation does not effect talin binding to PIPKIγ-90 as shown by co-immunoprecipitation (Supplemental Figure 1) . Together, these data suggest that talin1(L325R) does not markedly affect the binding of talin to integrins or PIPKIγ-90.
To assess activation of integrin α IIbβ3 in platelets from Tln1 (wt/fl) ,Cre+ or Tln1 (L325R/fl) ,Cre+ mice, we measured agonist-induced soluble fibrinogen binding.
Tln1
(L325R/fl) ,Cre+ platelets showed a striking reduction in fibrinogen binding despite similar amounts of talin and integrin expression as platelets from Tln1 (wt/fl) ,Cre+ mice ( Figure 1B and S3) . However, in the presence of manganese, which activates α IIbβ3 extrinsically, Tln1 (L325R/fl) ,Cre+ and Tln1 (wt/fl) ,Cre+ platelets bound similar amounts of fibrinogen indicating that upon activation, the α IIbβ3 expressed on Tln1 (L325R/fl) ,Cre+ platelets is capable of binding fibrinogen ( Figure 1B) . The defect in agonist-induced fibrinogen binding was not due to impaired agonist stimulation as agonist-induced Pselectin expression was similar in Tln1 (wt/fl) ,Cre+ and Tln1 (L325R/fl) ,Cre+ platelets ( Figure  S3 ). Since, there is evidence that β 1 and β 3 integrin activation may be regulated differently 15 , we measured β 1 integrin activation in Tln1 (L325R/fl) ,Cre+ and Tln1 (wt/fl) ,Cre+ platelets. Binding of 9EG7, an antibody that selectively binds to the active β 1 integrin conformation, was completely impaired in Tln1 (L325R/fl) ,Cre+ platelets ( Figure 1C ). The reduction in β 1 and β 3 integrin activation measured in Tln1 (L325R/fl) ,Cre+ platelets was similar to that previously reported in talin-deficient platelets 6 . Altogether, our results show that the talin1(L325R) mutation disrupts agonist-induced activation of both β 1 and β 3 integrins in platelets without markedly affecting the binding of talin to integrins or PIPKIγ-90.
Talin-dependent integrin activation is required for fibrin clot retraction.
Talin links integrins to the actin cytoskeleton and is important for transmitting mechanical force across the plasma membrane via integrins 16 . Since platelet retraction of fibrin clots requires integrins to be connected to the actin cytoskeleton 17, 18 , we tested the role of talin in platelet-mediated fibrin clot retraction. Indeed, talin-deficient platelets are defective in retracting a thrombin-induced clot demonstrating that talin is required to link the actin cytoskeleton to integrins during platelet clot retraction (Figure 2) . The clot retraction defect observed in talin-deficient platelets could be ascribable to impaired integrin activation, disruption of a talin-dependent mechanical linkage to integrins, or perturbing the function of talin-binding proteins such as PIPKIγ-90. To investigate these possibilities we examined clot retraction in Tln1 (L325R/fl) ,Cre+ platelets in which α IIbβ3 activation is impaired without disrupting talin binding to integrins or PIPKIγ-90.
Tln1
(L325R/fl) ,Cre+ platelets also showed defects in clot retraction, similar to talin-deficient platelets (Figure 2) . However, clot retraction by Tln1 (L325R/fl) ,Cre+ platelets, but not by talin-deficient platelets, could be rescued by 0.5mM MnCl 2 indicating that integrin activation, in addition to talin expression, is necessary for platelets to retract fibrin clots (Figure 2 ). The rescue of clot retraction by manganese was blocked by cytochalasin D or eptifibatide, showing that it was dependent on actin polymerization and α IIbβ3 ligand binding, respectively. Together these results show for the first time that both talindependent α IIbβ3 activation and talin-dependent linkage of the fibrin clot to the actin cytoskeleton via integrins are required for fibrin clot reaction by platelets. 
